Payment overview · 2025
General Payments
$667.57
29 reported records · 9 companies
Healthcare provider profile · identity verified
Ajith Purush, MBBS, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PRESCOTT, AZ · NPI 1699761437
Verified facts
What the public records show
CMS Open Payments records show Ajith Purush, MBBS, MD received $667.57 in general payments during 2025 across 29 reported records.
Sumitomo Pharma America, Inc. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $184.30 | 27.6% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $115.02 | 17.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.75 | 14.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $88.95 | 13.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.42 | 11.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.69 | 5.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.49 | 5.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.26 | 2.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.69 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $667.57 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $184.30 | 7 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $95.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.42 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $74.54 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.96 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.49 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| TENDRIL Normalized: tendril |
Device | Abbott Laboratories | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1097 | 307 |
| Atorvastatin Calcium | Atorvastatin Calcium | 998 | 276 |
| Losartan Potassium | Losartan Potassium | 840 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 540 | 151 |
| Lisinopril | Lisinopril | 535 | 157 |
| Simvastatin | Simvastatin | 384 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 377 | 114 |
| Metformin Hcl | Metformin Hcl | 312 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 296 | 82 |
| Gabapentin | Gabapentin | 281 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 84 |
| Omeprazole | Omeprazole | 252 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 66 |
| Allopurinol | Allopurinol | 237 | 65 |
| Potassium Chloride | Potassium Chloride | 225 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 224 | 68 |
| Fenofibrate | Fenofibrate | 223 | 62 |
| Furosemide | Furosemide | 213 | 67 |
| Trazodone Hcl | Trazodone Hcl | 212 | 73 |
| Pravastatin Sodium | Pravastatin Sodium | 209 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 59 |
| Prednisone | Prednisone | 195 | 150 |
| Duloxetine Hcl | Duloxetine Hcl | 188 | 56 |
| Spironolactone | Spironolactone | 177 | 52 |
| Memantine Hcl | Memantine Hcl | 160 | 39 |
| Alprazolam | Alprazolam | 150 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 42 |
| Eliquis | Apixaban | 143 | 38 |
| Ipratropium Bromide | Ipratropium Bromide | 140 | 57 |
| Meloxicam | Meloxicam | 139 | 46 |
| Montelukast Sodium | Montelukast Sodium | 137 | 48 |
| Synthroid | Levothyroxine Sodium | 129 | 33 |
| Atenolol | Atenolol | 126 | 34 |
| Tramadol Hcl | Tramadol Hcl | 122 | 35 |
| Famotidine | Famotidine | 120 | 38 |
| Alendronate Sodium | Alendronate Sodium | 119 | 38 |
| Ezetimibe | Ezetimibe | 119 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 118 | 31 |
| Sertraline Hcl | Sertraline Hcl | 118 | 32 |
| Bupropion Xl | Bupropion Hcl | 116 | 33 |
| Metformin Hcl Er | Metformin Hcl | 112 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 105 | 27 |
| Carvedilol | Carvedilol | 104 | 28 |
| Finasteride | Finasteride | 99 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 44 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 76 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 89 | 27 |
| Estradiol | Estradiol | 88 | 32 |
| Glimepiride | Glimepiride | 88 | 24 |
| Pregabalin | Pregabalin | 84 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 30 |
| Lorazepam | Lorazepam | 79 | 23 |
| Farxiga | Dapagliflozin Propanediol | 78 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 74 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 73 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 28 |
| Lovastatin | Lovastatin | 69 | 21 |
| Benazepril Hcl | Benazepril Hcl | 68 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 15 |
| Acyclovir | Acyclovir | 64 | 28 |
| Mirtazapine | Mirtazapine | 63 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 22 |
| Januvia | Sitagliptin Phosphate | 59 | 20 |
| Ozempic | Semaglutide | 59 | 15 |
| Nifedipine Er | Nifedipine | 58 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 26 |
| Propranolol Hcl | Propranolol Hcl | 57 | 17 |
| Gemtesa | Vibegron | 56 | 15 |
| Glipizide | Glipizide | 56 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 22 |
| Eszopiclone | Eszopiclone | 55 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Celecoxib | Celecoxib | 54 | 13 |
| Cephalexin | Cephalexin | 54 | 44 |
| Methylprednisolone | Methylprednisolone | 54 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 24 |
| Jardiance | Empagliflozin | 49 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 14 |
| Valacyclovir | Valacyclovir Hcl | 46 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 14 |
| Clonazepam | Clonazepam | 42 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 42 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 24 |
| Cefuroxime | Cefuroxime Axetil | 40 | 39 |
| Warfarin Sodium | Warfarin Sodium | 40 | 11 |
| Topiramate | Topiramate | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 21 |
| Armour Thyroid | Thyroid,pork | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 20 |
| Cefdinir | Cefdinir | 34 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 11 |
| Xarelto | Rivaroxaban | 34 | 11 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 22 |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | 11 |
| Azelastine Hcl | Azelastine Hcl | 27 | 16 |
| Creon | Lipase/Protease/Amylase | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Fluconazole | Fluconazole | 23 | 15 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nexletol | Bempedoic Acid | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 11 |
| Linzess | Linaclotide | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | 13 |
| Temazepam | Temazepam | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Motegrity | Prucalopride Succinate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $667.57 · 29 records | Sumitomo Pharma America, Inc. | AIRSUPRA, BREZTRI, EVENITY, FARXIGA, GEMTESA, JARDIANCE, JOT DX, Kerendia, OTEZLA, PROLIA, REPATHA, TENDRIL, TRELEGY ELLIPTA, Veozah, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error